ClinicalTrials.gg
RecruitingNCT07410078Updated Jul 28, 2026

Comparative Assessment of Oral Premedication Regimens in Pediatric Ambulatory Surgery

An interventional study of Oral Midazolam Premedication and Oral Midazolam plus Ibuprofen Premedication in Pediatric Anesthesia and Premedication, sponsored by Diskapi Yildirim Beyazit Education and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 4 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-07-28.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Diskapi Yildirim Beyazit Education and Research Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
4 Years to 12 Years
Sex
All
01

Study summary

This prospective, three-arm study aims to evaluate the effects of different oral premedication regimens on venipuncture tolerance in pediatric patients undergoing ambulatory surgery. Children aged 4-12 years scheduled for elective day-case procedures will receive oral midazolam alone, midazolam combined with ibuprofen, or midazolam combined with ketamine prior to anesthesia induction. The primary outcome is the proportion of children with well-tolerated venipuncture, assessed using standardized behavioral and pain scales. Secondary outcomes include anxiety levels, venipuncture success parameters, time to successful intravenous access, and parent and anesthesiologist satisfaction. In cases of inadequate premedication or failed venipuncture, a predefined rescue inhalational induction protocol will be applied to ensure patient safety. The study aims to identify clinically effective premedication strategies that may improve cooperation and reduce distress during intravenous cannulation in pediatric ambulatory anesthesia.

02

Conditions studied

  • Pediatric Anesthesia
  • Premedication

Browse trials for

Keywords

  • Pediatric Anesthesia
  • Premedication
  • Ambulatory surgery
  • Venipuncture tolerance
  • Anxiety
03

In context

Anxiety Disorders Unverified

7,201 studies on the registry are indexed under Anxiety Disorders; 1,682 are open to participants now.

This study's planned enrollment of 135 is above the median of 80 across 6,057 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Diskapi Yildirim Beyazit Education and Research Hospital is the lead sponsor of 71 studies on the registry; 12 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
4 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients aged 4-12 years
  • (ASA) physical status I-II
  • Scheduled for elective ambulatory (day-case) surgery
  • Eligible to receive oral premedication
  • Cognitive ability sufficient to complete behavioral and pain scale assessments
  • Written obtained from a parent or legal guardian

Exclusion criteria

Exclusion Criteria:

  • III or higher
  • Moderate to severe intellectual disability
  • Moderate to severe autism spectrum disorder
  • Known allergy or to midazolam, ketamine, or ibuprofen
  • History of sedative or opioid use within the previous 24 hours
  • Complete loss of premedication due to vomiting
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
135 participants (estimated)

Study arms

  • Active comparator
    Oral Midazolam Premedication

    Participants in this arm will receive oral midazolam as premedication at a dose of 0.5 mg/kg (maximum 15 mg), administered approximately 20 minutes before transfer to the operating room. The medications will be administered once prior to anesthesia induction. Venipuncture tolerance, anxiety, and pain-related outcomes will be assessed during intravenous cannulation.

    Procedure: Oral Midazolam Premedication

  • Active comparator
    Oral Midazolam plus Ibuprofen Premedication

    Participants in this arm will receive a combination of oral midazolam at a dose of 0.5 mg/kg (maximum 15 mg) and oral ibuprofen at a dose of 10 mg/kg, administered approximately 20 minutes before transfer to the operating room. The medications will be administered once prior to anesthesia induction. Venipuncture tolerance, anxiety, and pain-related outcomes will be assessed during intravenous cannulation.

    Procedure: Oral Midazolam plus Ibuprofen Premedication

  • Active comparator
    Oral Midazolam plus Ketamine Premedication

    Participants in this arm will receive oral midazolam at a dose of 0.5 mg/kg (maximum 15 mg) combined with oral ketamine at a dose of 3 mg/kg, administered approximately 20 minutes before transfer to the operating room. The medications will be administered once prior to anesthesia induction. Venipuncture tolerance, anxiety, and pain-related outcomes will be assessed during intravenous cannulation.

    Procedure: Oral Midazolam plus Ketamine Premedication

Interventions

  • ProcedureOral Midazolam Premedication

    Participants in this group will receive oral midazolam approximately 20 minutes before transfer to the operating room. The medication will be administered as a single dose prior to intravenous cannulation. Behavioral and pain-related assessments will be recorded during intravenous cannulation.

  • ProcedureOral Midazolam plus Ibuprofen Premedication

    Participants in this group will receive oral midazolam and oral ibuprofen approximately 20 minutes before transfer to the operating room. Both medications will be administered as a single dose prior to intravenous cannulation. Behavioral and pain-related assessments will be recorded during intravenous cannulation.

  • ProcedureOral Midazolam plus Ketamine Premedication

    Participants in this group will receive oral midazolam and oral ketamine approximately 20 minutes before transfer to the operating room. Both medications will be administered as a single dose prior to intravenous cannulation. Behavioral and pain-related assessments will be recorded during intravenous cannulation.

06

What researchers measure

Primary outcomes

  1. Proportion of Well-Tolerated Venipuncture

    The proportion of children with well-tolerated venipuncture during intravenous cannulation, assessed using the Children's Fear Scale (CFS), a validated 5-point scale ranging from 0 to 4 (0 = no fear; 4 = extreme fear). Well-tolerated venipuncture is defined as a CFS score \< 3 at the time of the venipuncture attempt.

    Time frame: During intravenous cannulation in the operating room

Secondary outcomes

  1. Anxiety Scores

    The mYPAS is an observational behavioral scale consisting of five domains (activity, vocalization, emotional expressivity, state of arousal, and use of parents). Scores are calculated using the original weighted scoring algorithm and generate a standardized total score ranging from 23.3 to 100, with higher scores indicating greater anxiety. Clinically significant anxiety is defined as mYPAS ≥ 30.

    Time frame: Assessed preoperatively before oral premedication and after premedication in the preoperative holding area.

  2. Pain Scores During Venipuncture

    Pain intensity assessed using the Wong-Baker Faces Pain Rating Scale, a validated 6-face scale scored from 0 to 10: 0 = no pain 10 = worst pain imaginable Higher scores indicate greater pain intensity.

    Time frame: During intravenous cannulation in the operating room

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07410078
Lead sponsor
Diskapi Yildirim Beyazit Education and Research Hospital
Responsible party
Elif Sule Ozdemir (Principal İnvestigator, Ankara Etlik City Hospital) — Principal investigator
First posted
Feb 13, 2026
Start date
Jul 26, 2026
Primary completion
Aug 19, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Jul 28, 2026

Study contacts

Elif Şule Özdemir Sezgi
Contact
elifsule-91@hotmail.com
00905059209638
Aslı Dönmez
Contact
aslidonmez@hotmail.com
00905322256473

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion